The people in our network are world leading experts in their fields related to pain and pain therapy.
MEET OUR CMO
PharmNovo is pleased to announce the appointment of Olof Breuer MD, Professor in clinical pharmacology, who will be acting as our Chief medical officer. Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies.
Read more →A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Read more →In memory of Hans G.
Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.
Read more →Patent granted in China
We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in China. PharmNovo AB is currently entering into regulatory toxicology studies with PN6047 – an exciting phase in the development of this biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins. In preclinical testing, our candidate effectively reduces neuropathic pain without any of the unwanted side effects of conventional opioids.
Read more →the Material on this website as well as all other material used in presentations or printed matters that have been prepared by PharmNovo AB, are general background information about PharmNovo’s activities as at the date of the publication or presentation. The information is given in summary form and does not purport to be complete. All information, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to → holding, purchasing or selling securities or other financial products or instruments and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice.
All securities and financial product or instrument transactions involve risks, which include (among others) the risk of adverse, financial or political developments and other risks. material on this website or in presentations may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to PharmNovo’s development opportunities and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward looking statements.
PharmNovo does not undertake any obligation to publicly or otherwise release the result of any revisions to these forward looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events or the development of pharmaceutical compounds providing negativa results. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside PharmNovo’s control. past performance and achieved development milestones are not reliable indications of future performance.
